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 Background: There is a growing recognition of sex-related disparities in atrial fibrillation (AF). However, limited data is avail-
able in Chinese AF patients.
 Material/Methods: We compared symptoms, quality of life (QoL), and treatment of AF according to sex from the China AF Registry 
study.
 Results: We studied 14 723 patients with non-valvular AF, of whom 5645 patients (38.3%) were female. Women were 
older than men (67.5±10.6 vs. 62.2±12.2). Compared to men, women had more comorbidities and a higher 
proportion of CHA2DS2-VASC score ³2. Women with AF experienced more severe or disabling symptoms than 
men (33.7% vs. 22.9% in age <75 group; 40.3% vs. 28.7% in age ³75 group; both P<0.0001). After multivariate 
analysis, women with AF still had lower QoL (OR 0.69; 95%CI, 0.63–0.76; P<0.0001). Women tended to have 
lower rates of ablation and rhythm-control drug use in those aged <75 years. Oral anticoagulant use was low 
and had no sex difference in AF patients with a CHA2DS2-VASC score ³2.
 Conclusions: In Chinese AF patients, women were older and more symptomatic, and had worse QoL. Despite all these dif-
ferences, women tended to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant 
was substantially underused in high stroke risk patients, regardless of sex.
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Background
Atrial fibrillation (AF), the most common arrhythmia, affect-
ed more than 33 million individuals in 2010 worldwide. It in-
creases the burden of stroke, heart failure, cognitive decline, 
and mortality [1,2]. Sex-related disparities in AF are increas-
ingly acknowledged [3–5]. Western countries have reported 
that clinical presentations and quality of life (QoL) differed 
between women and men with AF [6–8], and women with AF 
seemed to be under-treated compared to men [8–10]. However, 
sex differences are not well-examined in Chinese AF patients.
The China AF Registry study is an ongoing prospective regis-
try – one of the largest for Asian AF patients. It will provide an 
excellent opportunity to evaluate this knowledge gap. A better 
understanding of the sex differences in AF may have impor-
tant implications for quality improvement to reduce or even 
eliminate the sex disparities in AF care.
In this study, we used data from the China AF Registry to eval-
uate sex-related differences with the presentation, QoL, and 
treatment in Chinese AF patients.
Material and Methods
The China AF Registry study is a prospective, multicenter, ongo-
ing registry study of AF patients from 31 hospitals in Beijing, 
China. The design of the study had been published [11]. Local 
ethics committee approval was obtained and all participants 
provided signed informed consent.
Study population
The China AF Registry study had enrolled 19 515 AF patients 
from August 2011 to December 2016. In this analysis, we 
excluded 546 patients with mitral stenosis or valvular sur-
gery, 3380 patients without valid Atrial Fibrillation Effects on 
QualiTy of Life (AFEQT) questionnaires, and 866 patients with-
out European Heart Rhythm Association (EHRA) classification 
data. Finally, we included 14 723 participants. Figure 1 shows 
a flowchart of the study.
Data collection
Clinicians in participating hospitals collected data from medical 
charts. Collecting information included necessary socio-demo-
graphic data, AF type and duration, medical history, symptom 
and AFEQT questionnaires, and previous and current treat-
ment. We defined variables according to the ACC/AHA recom-
mendations on AF clinical data standards [12].
AF symptoms and QoL evaluation
AF-related symptoms were evaluated using the EHRA AF symp-
tom classification: no symptoms (EHRA I), mild symptoms 
(EHRA II), severe symptoms (EHRA III), and disabling symp-
toms (EHRA IV) [13].
A Chinese version of the AFEQT questionnaire was collected 
to assess health-related quality of life (HRQoL) at baseline. 
The AFEQT questionnaire is an AF-specific QoL evaluation which 
was recently developed and validated, supporting its use as a 
self-administered outcome measure in studies and as a tool 
for disease management [14]. The AFEQT questionnaire con-
tains 20 questions to evaluate the influence of AF on patients’ 
HRQoL during the past 4 weeks. The 18 items generate 3 indi-
vidual subscales – Symptoms, Daily Activities, and Treatment 
Concern. The last 2 indicate the Treatment Satisfaction domain. 
Overall AFEQT score is calculated based on the first 3 function-
al subscales. To be valid, the AFEQT questionnaires must have 
should at least half of the questions answered for each do-
main. AFEQT is scored with a 7-point Likert scale. The range of 
overall AFEQT or subscale scores is 0–100. Score 0 represents 
extremely disability and 100 indicates not at all limited. Thus, 
higher ratings indicate a better health status. For a percentage 
grading system of AFEQT scores, we set ³60 as passing scores 
indicating a ‘normal level’ of QoL, and the lower score sections 
as mild impairment of QoL (AFEQT scores 40–59), moderate 
impairment of QoL (AFEQT scores 20–39) and severe impair-
ment of QoL (AFEQT <20).
Statistical analysis
Continuous variables showed a mean±standard deviation or 
median (interquartile range); differences were assessed using 
the t test or Wilcoxon rank-sum test. Categorical variables are 




14,723 AF patients with
complete data at baseline
Excluded:
– 546 patients with mitral stenosis,
    valvular repair or replacement;
– 3380 AF patients without valid
    AFEQT questionnaires;
– 866 AF payients without EHRA
    classication data
Figure 1.  Flowchart of patients included. AF – atrial fibrillation; 
AFEQT – Atrial Fibrillation Effects on QualiTy of Life; 
EHRA = European Heart Rhythm Association.
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Table 1. Baseline characteristics according to sex and age.
Values are n/N (%), mean±SD or median (IQR). Denominators may be subject to missing data. BMI – body mass index; TIA – transient 
ischemic attack; SE – systemic embolism; eGFR – estimated glomerular filtration rate; AF – atrial fibrillation; IQR – interquartile range; 
CHA2DS2-VASc – cardiac failure or dysfunction, hypertension, age ³75 years (doubled), diabetes mellitus, stroke (doubled)–vascular 
disease, age 65–74 years, and sex category (Female).
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shown as numbers (percentages), and differences were com-
pared using the chi-square test.
Multivariate logistic regression analysis was performed to as-
sess the association between sex and QoL (the proportion of 
overall AFEQT score ³60). We corrected variables with poten-
tial influence on QoL, including age, body mass index (BMI), 
medical insurance and education, smoking, comorbidities 
(heart failure, hypertension, diabetes, previous thromboembo-
lism, vascular disease, hyperlipidemia, and renal dysfunction), 
AF type and duration, and current pharmacological treatments.
A two-tailed P value <0.05 was considered statistically signifi-
cant. We used SAS software 9.2 for data analyses.
Results
Among 14 723 patients with AF included in this study, 5645 
(38.3%) were women. Table 1 shows the characteristics of 
the patients. Since women were older on average by 5 years 
than men in the study (67.5±10.6 vs. 62.2±12.2, P<0.0001), we 
stratified the patients by age<75 and age ³75 groups. In both 
age groups, women had higher rates of heart failure, hyper-
tension, diabetes, and renal dysfunction, but a lower rate of 
vascular disease. Previous thromboembolism was similar ac-
cording to sex in both 2 age groups. Paroxysmal AF (65.3% 
vs. 55.8%, P<0.0001) and a CHA2DS2-VASC score ³2 (82.2% vs. 
45.3%, P<0.0001) was more prevalent in women for those 
aged <75 years.
AF-related symptoms
Female AF patients experienced more severe or disabling symp-
toms, with a higher proportion of EHRA III and IV classification, 
than men (35.6% vs. 24.0%, P<0.0001). Only 5.4% of women 
had no symptom, compared with 8.4% of men (Figure 2). Both 
age groups had similar results.
Quality of life
Figure 3 summarizes the proportion of the overall and each 
subscale of AFEQT scores by sex and age. Women had a lower 
percentage of an average QoL level (AFEQT ³60 scores) than 
men (54.1% vs. 66.7% in overall patients, 57.0% vs. 68.5% in 
age <75 years group and 46.8% vs. 58.4% in those aged ³75 
years group, both P<0.0001). The subscales of Symptoms, 
Daily Activities, and Treatment Concern all showed consis-
tent results (Figure 3). We also compared the mean value 
of overall AFEQT and each subscale score by sex, type of 
AF, and CHA2DS2-VASc scores, as shown in Figure 4. Women 
had lower overall AFEQT scores than men in those aged <75 
years (59.6±15.0 vs. 64.4±14.2, P<0.0001) and in older groups 
(57.5±15.1 vs. 61.2±15.3, P<0.0001). In newly diagnosed, par-
oxysmal AF, or persistent AF, women had lower overall AFEQT 
scores than men (All P <0.05 except for newly diagnosed AF 
in age ≥75 years group). Also, the AFEQT scores decreased in 
women across all CHA2DS2-VASc score groups. After the correc-
tion of demographics, comorbidities, and pharmacological treat-
ments, female sex remained independently associated with low-
er overall AFEQT score (OR 0.69; 95%CI, 0.63–0.76; P<0.0001).
AF-related treatment
We found no sex disparity in the prior use of electrical cardio-
version (Table 2). Women tended to receive less AF ablation 
(5.7% vs. 6.7%, P=0.025) in those aged <75 years, but not in 
patients age ³75 years (2.0% vs. 2.0%, P=0.949). In the group 
age <75, women were more likely to receive the rate control 
(51.4% vs. 46.9%, P<0.0001), but fewer received rhythm-con-
trol drugs (35.5% vs. 39.8%, P<0.0001). However, in the elderly 
group, current rhythm-control drug use had no significant dif-
ference between women and men (20.2% vs. 20.9%, P=0.664), 
while women still were more likely to receive rate control ther-
apy (65.2% vs. 59.3%, P=0.001). Both women and men with 
CHA2DS2-VASc score ³2 had low rates of oral anticoagulant 
(OAC) use (32.1% vs. 30.1% in those aged <75, P=0.081; and 
34.6% vs. 35.3% in those aged ³75, P=0.700).
Discussion
This massive Chinese AF cohort study indicated that wom-


























Figure 2.  Proportions of each EHRA classification by Sex. 
European Heart Rhythm Association (EHRA) AF 
symptoms classification was defined as no symptoms 
(EHRA I), mild symptoms (EHRA II), severe symptoms 
(EHRA III), and disabling symptoms (EHRA IV). 
F – Female; M – Male. * P<0.0001, Female vs. Male.
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more severe symptoms. After adjustment, women had lower 
QoL than men. Moreover, despite being much more likely to 
be symptomatic, women tended to receive less rhythm-con-
trol treatment in those aged <75. OAC use was low and had 
no sex difference in high stroke risk AF patients.
Prior extensive cohort studies have shown sex disparities in 
clinical features, treatment, and outcomes of AF in Western 
countries [6,7]. Female AF patients tended to be older, and 
were more likely to have a high burden of hypertension and 
heart failure with a preserved ejection fraction [15]. However, 
few studies have reported the association between sex and 
symptoms burden and QoL [8,16,17]. In a European survey, 
the EORP-AF study, women were found to have more symp-
toms, including palpitations, fear, and anxiety [7]. A system-
atic review suggested that asymptomatic AF was less com-
mon among women than among men [18]. A Europe survey 
reported that women had a lower general QoL using EuroQol 
scores [8]. The ORBIT-AF registry [6], a US-based observational 
study, has demonstrated that female AF patients had more sig-
nificant impairment of HRQoL as measured by specific AFEQT 
scores. Such sex differences were consistent with our large 
cohort study of Chinese AF patients, and a recently published 
systemic review has confirmed this [19]. The physical and psy-
chosomatic characteristics of female patients may be related 
to the observed differences in clinical characteristics and pre-
sentation [20–24]. Older age may also contribute to the differ-
ences in comorbidities, since women were older by an average 
of 5 years compared with men [20]. However, the differenc-
es in QoL were still significant after multivariable adjustment.
Guidelines indicate rhythm-control therapy to improve the 
symptom of AF patients (Class I, level B) [25]. In our study, 
younger (age <75) female AF patients were treated more con-
servatively with less catheter ablation or antiarrhythmic drugs 













































































Figure 3.  Proportions of each section in overall AFEQT and subscales scores by sex. AFEQT scores were classified as 4 sections: normal 
level of QoL (AFEQT scores ³60), mild impairment of QoL (AFEQT scores 40~59), moderate impairment of QoL (AFEQT scores 
20~39), and severe impairment of QoL (AFEQT <20). (A) Overall patients; (B) Patients aged <75 years old; (C) Patients aged 
³75 years old. AFEQT – Atrial Fibrillation Effects on QualiTy of Life; SY – symptoms; DA – daily activities; TC – treatment 
concern; TS – treatment satisfaction; F – Female; M – Male. * P<0.0001, ** P=0.025, *** P=0.01, Female vs. Male.
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more severe AF-related symptoms, and worse QoL. The ORBIT-AF 
study did not find sex-specific differences in the use of antiar-
rhythmic drugs [6], but women tended to receive less electric 
cardioversion or ablation therapy. The EORP-AF study report-
ed similar differences in treatment [7]. Women with symptom-
atic AF received less rhythm-control treatment, and we ob-
served the same treatment pattern in asymptomatic patients.
Nevertheless, these studies did not adjust for some critical fac-
tors, including age, comorbidities, duration, and symptom bur-
den of AF. The reasons for the disparities remain mostly un-
known, and potential explanations include sex differences in 
patient preferences and other clinical and socioeconomic fac-
tors [26]. Age may play an essential role in treatment strategy 
referral [15]. In our study, there was no sex-specific difference 
in rhythm-control treatment for patients ³75 years. The effi-
cacy and safety of antiarrhythmic drugs for women may influ-
ence the treatment preferences [27–29]. In addition, women 
tended to be less educated and less covered by health insur-
ance than men in our study. Thus, they may be more likely to 
delay seeking medical care and to accept more conservative 
treatment than men.
Our study observed that OAC for preventing stroke in high-risk 
patients was substantially underused regardless of sex, and 
women received OAC use similarly to men. Previous substan-
tial worldwide cohort research reported no sex differences in 
the use of OAC [30,31]. The EORP-AF and ORBIT-AF study found 
similar results [6, 7]. However, in another outpatient AF co-
hort, with a CHA2DS2-VASc score ³2, women were associated 
with less frequent prescription of OAC [32]. Although the pre-
vious research suggested that female sex is not an indepen-
dent risk factor of thromboembolism [33], women had poorer 
long-term outcomes among stroke survivors [34,35]. The ex-
tensive treatment gap in OAC use for stroke prevention re-
mains in Chinese AF patients of both sexes. Therefore, great 
efforts are warranted to promote OAC therapy among high-
risk patients with AF in China.
Limitations
First, the China AF Registry is a hospital-based registry; thus, 
patient selection bias is possible. Women may tend to not 
seek medical help until they experienced severe symptoms 
and significantly impaired QoL. However, these patients are 
representative of the patients we meet in clinical practice and 
thus are clinically relevant. Second, participating hospitals in 
this study are in Beijing, China’s capital; however, about half 
of the participants came from all over the country, thus in-
creasing the population samples’ representativeness. Finally, 
statistical methods cannot adequately correct for residual or 


















Prior electrical cardioversion  76 (1.9)  178 (2.4) 0.075  10 (0.6)  15 (0.9) 0.334
Prior AF catheter ablation  230 (5.7)  503 (6.7) 0.025  32 (2.0)  33 (2.0) 0.949
Current rhythm-control drugs  1437 (35.5)  2970 (39.8) <0.0001  332 (20.9)  327 (20.2) 0.664
 Propafenone  757 (18.7)  1213 (16.3) 0.001  108 (6.8)  116 (7.2) 0.661
 Amiodarone  564 (13.9)  1621 (21.7) <0.0001  157 (9.9)  171 (10.6) 0.501
 Sotalol  90 (2.2)  128 (1.7) 0.058  26 (1.6)  20 (1.2) 0.346
Current rate control drugs  2083 (51.4)  3502 (46.9) <0.0001  1038 (65.2)  959 (59.3) 0.001
 b-blocker  1921 (47.4)  3232 (43.3) <0.0001  895 (56.2)  807 (49.9) <0.0001
 Calcium-channel blockers  199 (4.9)  270 (3.6) 0.001  138 (8.7)  107 (6.6) 0.029
 Digoxin  252 (6.2)  384 (5.1) 0.016  234 (14.7)  201 (12.4) 0.062











Table 2. AF-related treatment stratified by sex and age.
Values are n (%), except where indicated. * Rates of current OAC are expressed as the number of patients received oral anticoagulant 
treatment divided by the number of patients who have indication for anticoagulation treatment (i.e., CHA2DS2-VASC ³2). AF – atrial 
fibrillation; OAC – oral anticoagulant; CHA2DS2-VASc – cardiac failure or dysfunction, hypertension, age ³75 years (doubled), diabetes 
mellitus, stroke (doubled)–vascular disease, age 65–74 years, and sex category (Female).
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Conclusions
In this prospective Chinese Registry, women with AF tended 
to be older, with more comorbidities, and had more severe 
symptoms and poorer QoL, compared to men. Despite all these 
factors, women tended to receive less rhythm-control treat-
ment than men in those aged <75 years. OAC was substan-
tially underused in high stroke risk patients regardless of sex.
Age<75
*




























































































































Figure 4.  Mean overall AFEQT and subscales scores by sex and type of AF and CHA2DS2-VASC Scores between females and males. 
(A) Mean overall AFEQT and subscales scores by sex; (B) Mean overall AFEQT and subscales scores by sex and type of AF. 
(C) Mean overall AFEQT and subscales scores by sex and CHA2DS2-VASC scores. AFEQT – Atrial Fibrillation Effects on QualiTy 
of Life; SY – symptoms; DA – daily activities; TC – treatment concern; TS – treatment satisfaction. * P<0.0001, ** P<0.05, 
Female vs. Male.
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